Table 1

In vitro susceptibilities of Candida spp. to isavuconazole, as determined with CLSI and EUCAST broth microdilution methods

SpeciesBMD methodaMIC (μg/ml)bEA (%) atc:
Range50%90%±1 dilution±2 dilutions
C. albicans (n = 42)CLSI≤0.008–0.030.0150.015100.0100.0
EUCAST≤0.008–0.015≤0.0080.015
C. glabrata (n = 25)CLSI0.12–80.5180.096.0
EUCAST0.12–412
C. parapsilosis (n = 22)CLSI≤0.008–0.060.030.0686.4100.0
EUCAST≤0.008–0.120.060.06
C. tropicalis (n = 14)CLSI0.03–0.50.060.585.7100.0
EUCAST0.015–10.060.5
C. krusei (n = 8)CLSI0.25–0.50.25NDd87.5100.0
EUCAST0.25–10.5ND
Total (n = 111)CLSI≤0.008–80.030.590.199.1
EUCAST≤0.008–40.031
  • a CLSI, Clinical and Laboratory Standards Institute; EUCAST, European Committee on Antimicrobial Susceptibility Testing.

  • b 50% and 90%, MIC values that encompass 50% and 90% of the isolates tested, respectively.

  • c EA, essential agreement of MIC values within 1 log2 or 2 log2 dilutions.

  • d ND, not determined due to the number of isolates (<10 isolates).